Semaglutide Reduces Cardiovascular Events by 20% in High-Risk Patients | SELECT Trial

The news coming out of the SELECT trial – a major study examining semaglutide’s impact on cardiovascular health – is resonating far beyond the medical journals. Although the initial headlines focused on a 20% reduction in major adverse cardiovascular events for patients with heart disease and obesity, a deeper dive reveals a potentially significant benefit for those grappling with liver fibrosis. And here in Chicago, a city with a diverse population and a growing awareness of metabolic health, this is a conversation worth having. The prespecified analysis, published in Nature Medicine, highlights that semaglutide’s positive effects were even more pronounced in individuals at higher risk of substantial liver fibrosis, as measured by the Fibrosis-4 (FIB-4) index.

Semaglutide and the Interplay of Heart and Liver Health

For years, the connection between obesity, metabolic dysfunction, and liver disease has been increasingly clear. What’s often referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – formerly known as non-alcoholic fatty liver disease (NAFLD) – is now recognized as a major public health concern. It’s not simply a liver problem; it’s a systemic issue intricately linked to cardiovascular health, diabetes, and overall metabolic well-being. The SELECT trial data suggests that semaglutide, initially developed for diabetes management, may offer a dual benefit, addressing both cardiovascular risk and potentially slowing the progression of liver fibrosis.

View this post on Instagram

The study specifically examined patients with atherosclerotic cardiovascular disease and obesity, but *without* diabetes. This is crucial. It demonstrates that semaglutide’s benefits extend beyond those with pre-existing diabetes, opening up potential treatment avenues for a broader population. Researchers assessed liver biochemical tests and steatosis risk using the fatty liver index over a 104-week period. The results were compelling: semaglutide led to a 28% greater decrease in fatty liver index compared to placebo. This wasn’t a minor difference; the hazard ratio of 0.72 (with a 95% confidence interval of 0.71–0.73) indicates a statistically significant reduction.

Decoding the Fibrosis-4 Index and its Significance in Chicago

Understanding the FIB-4 index is key to grasping the implications of this research. It’s a simple, non-invasive blood test that estimates the level of liver fibrosis – scarring – using readily available data: age, platelet count, AST (aspartate aminotransferase), and ALT (alanine aminotransferase). A higher FIB-4 score suggests a greater degree of fibrosis. The SELECT trial analyzed subgroups based on different FIB-4 thresholds (≥1.3, age-specific thresholds, and >2.67), revealing that the reduction in major adverse cardiovascular events (MACE) was most significant in those with higher baseline scores.

Here in Chicago, with its diverse communities and varying access to healthcare, the FIB-4 index is becoming an increasingly critical tool for identifying individuals at risk. Hospitals like Northwestern Memorial Hospital and the University of Chicago Medical Center are actively utilizing this test as part of their routine metabolic health assessments. The Cook County Health system, serving a large and often underserved population, is also likely to benefit from the accessibility and cost-effectiveness of the FIB-4 index.

The SELECT Trial: A Closer Look at the Data

The reduction in MACE observed in the SELECT trial was 26% (HR 0.74, 95% CI 0.63–0.88, P=0.0004) for those with a baseline FIB-4 score of ≥1.3. Breaking this down further, the reduction was 21% (HR 0.79, 95% CI 0.63–0.98, P=0.035) for age-specific thresholds and 34% (HR 0.66, 95% CI 0.39–1.10, P=0.11) for those with FIB-4 > 2.67. While the highest reduction (34%) wasn’t statistically significant, the trend suggests a potentially even greater benefit for individuals with more advanced fibrosis. It’s important to note that this was a *prespecified secondary analysis*, meaning it wasn’t the primary focus of the trial, but the findings are nonetheless encouraging.

The implications extend beyond simply reducing cardiovascular events. Liver fibrosis, if left unchecked, can progress to cirrhosis and liver failure, requiring a liver transplant. The potential for semaglutide to slow or even reverse fibrosis could significantly reduce the burden of liver disease, a growing concern nationally and within Illinois. The clinical trial registration number, NCT03574597, provides a pathway for further investigation into the trial’s methodology and complete data set.

Navigating the Implications: A Local Resource Guide for Chicago Residents

Given my background in biomedical research, and understanding the complexities of metabolic health, if these findings resonate with you or a loved one in the Chicago area, here are three types of local professionals Try to consider consulting:

Board-Certified Hepatologists: Look for a hepatologist affiliated with a major Chicago hospital (Northwestern, University of Chicago, Rush). Crucially, verify they have experience interpreting FIB-4 results *and* developing comprehensive management plans for MASLD. Don’t hesitate to question about their experience with newer therapies like semaglutide.
Registered Dietitian Nutritionists (RDNs) specializing in Metabolic Health: A skilled RDN can help you develop a personalized dietary plan to address underlying metabolic dysfunction and support liver health. Seek out an RDN with a certification in diabetes care and education (CDCES) or a strong focus on liver disease. They should be able to translate complex medical information into practical, actionable steps.
Cardiologists with Expertise in Cardio-Metabolic Risk: The SELECT trial underscores the interconnectedness of heart and liver health. A cardiologist who understands this connection can provide a holistic assessment of your cardiovascular risk and recommend appropriate interventions, potentially including semaglutide in consultation with your hepatologist. Look for a cardiologist affiliated with a leading Chicago heart center.

Ready to uncover trusted professionals? Browse our complete directory of top-rated healthcare experts in the Chicago area today.